Dash Acquisitions Inc. Has $13.70 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Dash Acquisitions Inc. increased its stake in Thermo Fisher Scientific Inc. by 5.8%, now holding a total of 33,796 shares worth approximately $13.7 million.
• Thermo Fisher Scientific reported a quarterly earnings per share (EPS) of $5.36, surpassing analysts' expectations of $5.22, alongside a revenue of $10.86 billion.
• Institutional investors own 89.23% of Thermo Fisher Scientific's stock, indicating strong institutional confidence in the company's performance.

Dash Acquisitions Inc. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 33,796 shares of the medical research company's stock after purchasing an additional 1,844 shares during the quarter. Thermo Fisher Scientific makes up about 2.9% of Dash Acquisitions Inc.'s holdings, making the stock its 13th biggest position. Dash Acquisitions Inc.'s holdings in Thermo Fisher Scientific were worth $13,703,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Mondrian Investment Partners LTD grew its stake in Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock valued at $106,738,000 after buying an additional 127,357 shares during the last quarter. Caledonia Investments PLC grew its position in shares of Thermo Fisher Scientific by 11.5% in the second quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company's stock valued at $45,299,000 after purchasing an additional 11,500 shares during the last quarter. Foresight Group Ltd Liability Partnership grew its holdings in Thermo Fisher Scientific by 3,242.7% in the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock valued at $29,113,000 after buying an additional 56,747 shares during the last quarter. Advisors Capital Management LLC grew its holdings in Thermo Fisher Scientific by 6.7% in the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock valued at $63,201,000 after buying an additional 7,967 shares during the last quarter. Finally, New England Research & Management Inc. grew its holdings in Thermo Fisher Scientific by 28.6% in the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company's stock valued at $1,033,000 after buying an additional 567 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 0.1%

Shares of NYSE:TMO opened at $525.08 on Wednesday. The company has a market capitalization of $198.28 billion, a PE ratio of 30.37, a P/E/G ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company's fifty day moving average is $491.00 and its 200-day moving average is $448.20.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Raymond James Financial restated an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. William Blair started coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating on the stock. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. Finally, Barclays lifted their price target on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a research note on Thursday, October 2nd. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $589.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.